> GlaxoSmithKline is now ready to launch its vaccine against cervical cancer, Cervarix, in the E.U--and analysts expect revenues of $2 billion to $5 billion there, based on rival Gardisil's performance in the U.S.  Report [1]

> Ranbaxy Laboratories inked a licensing deal with Australia's Sirtex Medical to market the colorectal/liver cancer drug Sir-Spheres. Report [2]

> Cardinal Health tapped CEO R. Kerry Clark as chairman, to replace retiring chairman and founder Robert D. Walker. Report [3]

> Pfizer got EU approval for Celsentri (maraviroc), its new, first-in-class HIV fighter. Report [4]

> Bristol-Myers will buy its drug-development partner Adnexus Therapeutics for about $415 million. Report [5]

> Novartis got the E.U. nod for its Exelon patch, a treatment for mild to moderate Alzheimer's. Report [6]

> The EU's drug safety committee recommended approval for Schering-Plough's combination hepatitis C treatment. Report [7]

And Finally... Here's another drug safety dilemma to round out the day's news: Patients often take handfuls of different prescription drugs daily, in potentially deadly combinations, along with OTC chasers for good measure. Report [8]